WINSTON-SALEM, N.C., Feb. 15 (UPI) -- An experimental drug tested in mice can reduce the potentially life-threatening symptoms of the common autoimmune disorder lupus
canada goose jacka, a new study released early Saturday concludes.
Researchers led by Dr. Mishra Nilamadhab
kjøp canada goose, a rheumatologist and clinical immologist at Wake Forest University Baptist Medical Center, used a drug called Trichostatin or TSA, a compound that is produced by fungus.
They combined TSA with another drug
abercrombie and fitch pas cher, a synthetic compound called suberonylanilide hydroxamic acid or SAHA. The therapy is meant to treat a particular form of the disease called systemic lupus, which affects about 70 percent of all lupus patients.
In the study
canada goose jakker billig, half of the mice with a lupus received the combined therapy while the other half remained untreated. Compared to the untreated mice, TSA in the treated animals lead to significant reductions in protein in the animals' urine
www.abercrombieetfitchfr.com, a sure sign of trouble, and also reductions in kidney inflammation and no signs of enlargement of the spleen. Half of all the untreated mice in the study died with 20 weeks from kidney failure.
"Most common cause of death in the human lupus is the kidney failure, so if we can protect the kidneys in the mice, we think it could work the same in the human lupus," Mishra told United Press International.
The surviving untreated mice also developed massive spleens, researchers report in the February 14 issue of Journal of Clinical Investigation.
The way the TSA and SAHA work together is by targeting the expression, or behavior, of the genes associated with the lupus with affecting other genes, Mishra explained. "We found it suppressed the bad genes
www.canadagoosesjackor.info," he said.
By affecting the lupus's genetic roots, this treatment also reduced side effects from lupus
Canada goose, a disease in which the body's own immune system turns on itself and even attacks vital organs. Human lupus patients also can experience secondary complications from their illness including diabetes, infection and osteoporosis.
"We presume this drug will not only help in treatment for lupus itself, but will also prevent complications," Mishra said. "We also think this drug could be helpful in (treating) diabetes."
The Lupus Foundation of America estimates 1.4 million Americans have lupus. It is much more prevalent among young women and more common among African-Americans, Native-Americans, Hispanics and Asians than Caucasians.
Mishra added scientists had first tested this TSA-SAHA drug combination on lupus cells extracted from people and studied under the microscope. The therapy was found to be effective in the laboratory tests. Now that's it's also been found effective in animals studies, Mishra said the preliminary results are encouraging.
Dr. David Pisetsky, chief of rheumatology at Duke University Medical Center in Durham, N.C., said not all successful studies in animals translates to a new drug opportunity for patients.
"It's basically the first step," Pisetsky told UPI. "You have an interesting compound or an interesting approach that could affect the immune system."
However, "developing drugs for lupus can be more difficult because of the nature of the disease," he said. "Drugs may make it or may not make it for variety reasons ... on basis of just one study
Sweat abercrombie & fitch, it's difficult to know that. You just need more data to be able to go the next step in terms of drug development."
--
(Reported by Katrina Woznicki, UPI Science News
www.ektecanadagoose.com, in Washington)Related Topics Articles：
